• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 通过细胞间传播。

SARS-CoV-2 spreads through cell-to-cell transmission.

机构信息

Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210.

Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.

出版信息

Proc Natl Acad Sci U S A. 2022 Jan 4;119(1). doi: 10.1073/pnas.2111400119.

DOI:10.1073/pnas.2111400119
PMID:34937699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8740724/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible coronavirus responsible for the global COVID-19 pandemic. Herein, we provide evidence that SARS-CoV-2 spreads through cell-cell contact in cultures, mediated by the spike glycoprotein. SARS-CoV-2 spike is more efficient in facilitating cell-to-cell transmission than is SARS-CoV spike, which reflects, in part, their differential cell-cell fusion activity. Interestingly, treatment of cocultured cells with endosomal entry inhibitors impairs cell-to-cell transmission, implicating endosomal membrane fusion as an underlying mechanism. Compared with cell-free infection, cell-to-cell transmission of SARS-CoV-2 is refractory to inhibition by neutralizing antibody or convalescent sera of COVID-19 patients. While angiotensin-converting enzyme 2 enhances cell-to-cell transmission, we find that it is not absolutely required. Notably, despite differences in cell-free infectivity, the authentic variants of concern (VOCs) B.1.1.7 (alpha) and B.1.351 (beta) have similar cell-to-cell transmission capability. Moreover, B.1.351 is more resistant to neutralization by vaccinee sera in cell-free infection, whereas B.1.1.7 is more resistant to inhibition by vaccinee sera in cell-to-cell transmission. Overall, our study reveals critical features of SARS-CoV-2 spike-mediated cell-to-cell transmission, with important implications for a better understanding of SARS-CoV-2 spread and pathogenesis.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是一种高度传染性的冠状病毒,引发了全球 COVID-19 大流行。在此,我们提供证据表明,SARS-CoV-2 通过刺突糖蛋白在培养物中通过细胞-细胞接触传播。SARS-CoV-2 刺突比 SARS-CoV 刺突更有效地促进细胞间传播,这在一定程度上反映了它们不同的细胞-细胞融合活性。有趣的是,用内体进入抑制剂处理共培养的细胞会损害细胞间传播,这表明内体膜融合是一种潜在的机制。与无细胞感染相比,COVID-19 患者恢复期血清或中和抗体对 SARS-CoV-2 的细胞间传播的抑制作用较弱。尽管血管紧张素转换酶 2 增强了细胞间传播,但我们发现它不是绝对必需的。值得注意的是,尽管无细胞感染力存在差异,但真正令人关注的变异株(VOC)B.1.1.7(阿尔法)和 B.1.351(贝塔)具有相似的细胞间传播能力。此外,B.1.351 在无细胞感染中对疫苗接种者血清的中和作用更具抵抗力,而 B.1.1.7 在细胞间传播中对疫苗接种者血清的抑制作用更具抵抗力。总体而言,我们的研究揭示了 SARS-CoV-2 刺突介导的细胞间传播的关键特征,对更好地理解 SARS-CoV-2 的传播和发病机制具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/9501394dba21/pnas.2111400119fig07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/4c257d61f246/pnas.2111400119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/44c8c69b6c5b/pnas.2111400119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/79e63329eb33/pnas.2111400119fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/79c69b0cc62e/pnas.2111400119fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/9f7b6d298d9a/pnas.2111400119fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/10059112892a/pnas.2111400119fig06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/9501394dba21/pnas.2111400119fig07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/4c257d61f246/pnas.2111400119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/44c8c69b6c5b/pnas.2111400119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/79e63329eb33/pnas.2111400119fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/79c69b0cc62e/pnas.2111400119fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/9f7b6d298d9a/pnas.2111400119fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/10059112892a/pnas.2111400119fig06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de79/8740724/9501394dba21/pnas.2111400119fig07.jpg

相似文献

1
SARS-CoV-2 spreads through cell-to-cell transmission.SARS-CoV-2 通过细胞间传播。
Proc Natl Acad Sci U S A. 2022 Jan 4;119(1). doi: 10.1073/pnas.2111400119.
2
SARS-CoV-2 Spreads through Cell-to-Cell Transmission.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)通过细胞间传播扩散。
bioRxiv. 2021 Jun 1:2021.06.01.446579. doi: 10.1101/2021.06.01.446579.
3
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
4
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
5
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.SARS-CoV-2 变体 B.1.351 和 P.1 逃避中和抗体。
Cell. 2021 Apr 29;184(9):2384-2393.e12. doi: 10.1016/j.cell.2021.03.036. Epub 2021 Mar 20.
6
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
7
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.一种具有罕见遗传特征和结构识别模式的抗体对 SARS-CoV-2 关注变种的有效中和作用。
Cell Rep. 2021 Oct 5;37(1):109784. doi: 10.1016/j.celrep.2021.109784. Epub 2021 Sep 16.
8
Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma.利用 COVID-19 恢复期血浆阻断 SARS-CoV-2 刺突蛋白介导的细胞-细胞融合。
Sci Rep. 2021 Mar 10;11(1):5558. doi: 10.1038/s41598-021-84840-3.
9
Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.用于评估人类临床样本中SARS-CoV-2(COVID-19)病毒中和抗体的可扩展微中和试验
Viruses. 2021 May 12;13(5):893. doi: 10.3390/v13050893.
10
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.SARS-CoV-2 变体 B.1.617.1 (Kappa)、B.1.617.2 (Delta) 和 B.1.618 的细胞进入和免疫逃逸特性。
mBio. 2022 Apr 26;13(2):e0009922. doi: 10.1128/mbio.00099-22. Epub 2022 Mar 10.

引用本文的文献

1
Antiviral nanomedicine: Advantages, mechanisms and advanced therapies.抗病毒纳米药物:优势、作用机制及先进疗法
Bioact Mater. 2025 Jun 5;52:92-122. doi: 10.1016/j.bioactmat.2025.05.030. eCollection 2025 Oct.
2
SUMOylation of SARS-CoV-2 spike protein is a key target for broad-spectrum antiviral therapy.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的类泛素化修饰是广谱抗病毒治疗的关键靶点。
Theranostics. 2025 May 25;15(13):6369-6386. doi: 10.7150/thno.111256. eCollection 2025.
3
Deletion of the Envelope gene attenuates SARS-CoV-2 infection by altered Spike localization and increased cell-to-cell transmission.

本文引用的文献

1
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.联合抑制宿主进入因子 PIKfyve 激酶和 TMPRSS2 蛋白酶对 SARS-CoV-2 感染的协同阻断。
J Virol. 2021 Oct 13;95(21):e0097521. doi: 10.1128/JVI.00975-21. Epub 2021 Aug 18.
2
SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)突变、疫苗与免疫:关注变异株的影响
Signal Transduct Target Ther. 2021 May 22;6(1):203. doi: 10.1038/s41392-021-00623-2.
3
Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19.
包膜基因的缺失通过改变刺突蛋白的定位和增加细胞间传播来减弱新冠病毒感染。
bioRxiv. 2025 May 23:2025.05.20.655126. doi: 10.1101/2025.05.20.655126.
4
Chikungunya virus and other emerging arthritogenic alphaviruses.基孔肯雅病毒及其他新出现的致关节炎甲病毒
Nat Rev Microbiol. 2025 May 7. doi: 10.1038/s41579-025-01177-8.
5
Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2' site.捕获严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的融合中间构象需要受体结合以及在S1/S2或S2'位点的切割。
PLoS Pathog. 2025 Apr 8;21(4):e1012808. doi: 10.1371/journal.ppat.1012808. eCollection 2025 Apr.
6
Strain- and vaccine-specific effects of serum antibodies in the protection of intestinal SARS-CoV-2 infection.血清抗体在预防肠道 SARS-CoV-2 感染中的菌株特异性和疫苗特异性作用。
medRxiv. 2025 Mar 28:2025.03.24.25324570. doi: 10.1101/2025.03.24.25324570.
7
RAB5 is a host dependency factor for the generation of SARS-CoV-2 replication organelles.RAB5是新冠病毒复制细胞器生成的宿主依赖因子。
mBio. 2025 May 14;16(5):e0331424. doi: 10.1128/mbio.03314-24. Epub 2025 Apr 1.
8
SARS-CoV2 infection triggers inflammatory conditions and astrogliosis-related gene expression in long-term human cortical organoids.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染会引发长期人类皮质类器官中的炎症反应和与星形胶质细胞增生相关的基因表达。
Stem Cells. 2025 May 27;43(6). doi: 10.1093/stmcls/sxaf010.
9
T-Cell-Dependent Bispecific IgGs Protect Aged Mice From Lethal SARS-CoV-2 Infection.T细胞依赖性双特异性IgG可保护老年小鼠免受致死性SARS-CoV-2感染。
Adv Sci (Weinh). 2025 Apr;12(15):e2406980. doi: 10.1002/advs.202406980. Epub 2025 Feb 20.
10
A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses.一种源自鲨鱼的广泛中和纳米抗体,靶向沙贝病毒S2结构域上的高度保守表位。
J Nanobiotechnology. 2025 Feb 15;23(1):110. doi: 10.1186/s12951-025-03150-2.
对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的固有免疫和炎症反应:对冠状病毒病(COVID-19)的影响
Cell Host Microbe. 2021 Jul 14;29(7):1052-1062. doi: 10.1016/j.chom.2021.05.004. Epub 2021 May 17.
4
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.针对 SARS-CoV-2 的中和抗体反应在有症状的 COVID-19 中是持久的,对生存至关重要。
Nat Commun. 2021 May 11;12(1):2670. doi: 10.1038/s41467-021-22958-8.
5
Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States.美国早期引入和传播的 SARS-CoV-2 变异株 B.1.1.7。
Cell. 2021 May 13;184(10):2595-2604.e13. doi: 10.1016/j.cell.2021.03.061. Epub 2021 Apr 3.
6
Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.关注的 SARS-CoV-2 变体 B.1.1.7、B.1.351 或 P.1 的特征:来自七个欧盟/欧洲经济区国家的数据,2020 年第 38 周至 2021 年第 10 周。
Euro Surveill. 2021 Apr;26(16). doi: 10.2807/1560-7917.ES.2021.26.16.2100348.
7
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
8
Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.SARS-CoV-2 新变体的传染性更高与 K417N/T、E484K 和 N501Y 突变有关:来自结构数据的见解。
J Cell Physiol. 2021 Oct;236(10):7045-7057. doi: 10.1002/jcp.30367. Epub 2021 Mar 23.
9
The first 12 months of COVID-19: a timeline of immunological insights.COVID-19 出现的头 12 个月:免疫学研究进展一览。
Nat Rev Immunol. 2021 Apr;21(4):245-256. doi: 10.1038/s41577-021-00522-1. Epub 2021 Mar 15.
10
Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.可溶性 ACE2 通过与肾素-血管紧张素系统相关蛋白的相互作用介导 SARS-CoV-2 的细胞进入。
Cell. 2021 Apr 15;184(8):2212-2228.e12. doi: 10.1016/j.cell.2021.02.053. Epub 2021 Mar 2.